SecBot SecBot
Insider Cluster (2 insiders) ·Filed Aug 17, 2026

ORKA

Oruka Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonweeks Processed3mo ago
Insider cluster: 2 insiders, $653K total
Actionable Insight • Neutral

This cluster is a non-event for the stock, option exercises and subsequent sales by C-suite insiders are routine post-vesting liquidity events. Monitor upcoming pipeline catalysts (Week 28 EVERLAST-A data end-Q3 2026, ORKA-001 Phase 3 start 1H 2027) for actual equity-moving information.

DirectionNeutral
Confidencehigh
Horizonweeks

ORKA-001

▲ Bullish Named in this insider cluster
Impact
Phase
Phase 2b
Time to market
If Phase 3 trials begin in 1H 2027 and run successfully, a BLA submission and potential FDA approval would likely be several years away, possibly in the 2029-2030 timeframe. The company has stated its $1.1 billion cash position funds operations through a BLA filing.
Next catalyst
None dated

What to watchThe key catalyst to watch is the EVERLAST-A 52-week data expected in December 2026, which will demonstrate whether ORKA-001's skin-clearing responses hold up a full year after just two doses. Strong durability would reinforce the ultra-durable dosing thesis and support the Phase 3 design. Weak durability would challenge the core value proposition. Phase 3 initiation in 1H 2027 and ORKA-002 Phase 2 data in Q1 2027 are secondary catalysts. The $1.1B cash runway removes financing overhang through a BLA filing.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$113.08
T+0 close · Aug 17, 2026 · via day close
Latest settled
−3.17%
T+60 · $109.50
Vs SPY
−1.12%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 18 $113.08entry
  2. T+1 · 3mo ago −3.00%α −3.21% · $109.69
  3. T+5 · 3mo ago −9.96%α −9.76% · $101.82
  4. T+20 · 2mo ago −16.18%α −15.19% · $94.78
  5. T+60 · 6d ago −3.17%α −1.12% · $109.50

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two senior insiders at Oruka Therapeutics (CMO and General Counsel) executed large-derivative exercises and sold shares on the open market for a total of $653K in net sales in the week following Q2 2026 earnings. The sales follow option exercises, not direct bearish conviction, and represent ~0.009% of the $7.4B market cap, well below materiality thresholds. The insider cluster is a routine post-vesting pattern, not a predictive signal.

Key Financial Metrics

Direction
selling
Total Value
$653.0K
Insiders
2

Key Facts

  • CMO Goncalves sold ~7,000 shares for ~$784K; General Counsel Quinlan sold ~52,000 shares for ~$5.6M, both after exercising options at $0–$12.50 strike prices.
  • Total open-market sales of ~$653K represent ~0.009% of Oruka's $7.4B market cap, trivial.
  • Insider activity occurred 7 days after Q2 2026 earnings (consensus-beating EPS loss of $0.55 vs $0.49) following an upsized $700M April 2026 public offering; no material negative catalyst.

Financial Impact

~$6.4M in aggregate insider sales (including option exercises), but open-market net sales of $653K, immaterial relative to $7.4B market cap and $1.1B cash balance.

dilution

Risk Factors

  • Insider sales could pick up in volume or frequency ahead of clinical readouts, signaling reduced conviction.
  • Pre-commercial biotech's sole catalyst is pipeline data, any negative readout would be highly material.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ORKA-1787004617759

Track record

40 reports on ORKA

Performance horizon

7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +80.05% at T+60 after the Jun 1, 2026 report. 11 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry price pending
  3. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
  4. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
  5. Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
  6. Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
  7. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 Now $99.24 −9.37% settles Dec 9
  8. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
  9. Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
  10. Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
Showing 10 of 40

US Market Status

Market Closed · Opens Wed (10h 53m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 17, 2026